Hinz Andreas, Mehnert Anja, Ernst Jochen, Herschbach Peter, Schulte Thomas
Department of Medical Psychology and Medical Sociology, University of Leipzig, Philipp-Rosenthal-Str. 55, 04103, Leipzig, Germany,
Support Care Cancer. 2015 Jun;23(6):1579-87. doi: 10.1007/s00520-014-2516-5. Epub 2014 Nov 21.
Many cancer patients experience fear of progression (FoP). The purpose of this study was to test psychometric properties of the questionnaire FoP-Q-12, to examine age and gender differences of FoP, and to explore prognostic factors of FoP.
A sample of 2059 patients with a cancer diagnosis who had participated in a cancer rehabilitation program was examined 6 months after discharge from the rehabilitation clinic. Participants filled in the Fear of Progression questionnaire FoP-Q-12, the Hospital Anxiety and Depression Scale (anxiety subscale), and the Generalized Anxiety Disorder Questionnaire GAD-2 and answered a list of questions concerning their cancer disease.
Reliability of the FoP-Q-12 (Cronbach's alpha = 0.90) was good. While exploratory factorial analysis supported the one-dimensional structure of the FoP-Q-12, confirmatory factorial analysis only partially supported the one-dimensional model. A proportion of 16.7 % of the sample scored above the FoP-Q-12 cutoff score. Females showed higher FoP scores than males (effect size d = 0.52), and older patients had slightly lower levels of FoP than younger patients (d = 0.17). There were substantial and significant correlations between FoP-Q-12 and Hospital Anxiety and Depression Scale (HADS) anxiety (r = 0.71) as well as GAD-2 anxiety (r = 0.57). The highest FoP mean scores were found for the following cancer locations: ovary (M = 29.5), thyroid gland (M = 28.8), and breast (M = 27.9), while the lowest scores were found for Hodgkin lymphoma (M = 23.6), testis (M = 21.8), and prostate (M = 21.7).
The FoP-Q-12 proved to be a valid instrument for measuring fear of progression in cancer patients.
许多癌症患者会经历疾病进展恐惧(FoP)。本研究旨在测试FoP-Q-12问卷的心理测量特性,研究FoP的年龄和性别差异,并探索FoP的预后因素。
对2059名参与癌症康复项目且已从康复诊所出院6个月的癌症确诊患者进行抽样调查。参与者填写疾病进展恐惧问卷FoP-Q-12、医院焦虑抑郁量表(焦虑分量表)和广泛性焦虑障碍问卷GAD-2,并回答一系列有关其癌症疾病的问题。
FoP-Q-12的信度良好(克朗巴哈系数α=0.90)。探索性因子分析支持FoP-Q-12的一维结构,但验证性因子分析仅部分支持该一维模型。16.7%的样本得分高于FoP-Q-12的临界分数。女性的FoP得分高于男性(效应量d=0.52),老年患者的FoP水平略低于年轻患者(d=0.17)。FoP-Q-12与医院焦虑抑郁量表(HADS)焦虑(r=0.71)以及GAD-2焦虑(r=0.57)之间存在显著且实质性的相关性。以下癌症部位的FoP平均得分最高:卵巢(M=29.5)、甲状腺(M=28.8)和乳腺(M=27.9),而霍奇金淋巴瘤(M=23.6)、睾丸(M=21.8)和前列腺(M=21.7)的得分最低。
FoP-Q-12被证明是测量癌症患者疾病进展恐惧的有效工具。